The Role of Digital Health in Immuno-oncology Therapy Development and Adoption

The FDA is currently overseeing 800 active applications for cell and gene therapies in immuno-oncology (IO), therapies which take advantage of patients’ immune biology to fight cancer. By 2025 they could be approving 10-20 applications each year.

The timing is impeccable, with one-fifth of global pharma sales is spent on oncology, and 40% of US adults will receive a cancer diagnosis in their lifetime. But, it also make treatment decisions more challenging for oncologists: how can a doctor best match patients to appropriate treatments?

In our new white paper, The Role of Digital Health in Immuno-oncology Therapy and Adoption, we explore both the challenges and opportunities that this golden era in cancer treatment is unlocking. 

 Insights from AstraZeneca, Bristol-Myers Squibb, Cancer Treatment Centers of America, and more

To explore the rapidly evolving immuno-oncology industry and its intersection with digital, BrightInsight spoke with executives from top biopharma companies and oncologists from leading health systems, including:

Joachim Reischl, Vice President, Head of Diagnostic Sciences, AstraZeneca, shared how his team is focused on the entire patient journey:

“We need to think about the patient journey. We should work toward treatment tools that capture the patient journey more holistically and go beyond a specific treatment modality. This may help to reduce the current fragmentation and improve the patient journey.”

Download our white paper to learn more about the role that digital is playing in helping to realize and accelerate the impact of IO therapy, including:

We hope it gives you valuable insights into the benefits of doubling down on digital health solutions when developing IO therapies, and shows you how a regulated platform like BrightInsight’s can help you leverage data more efficiently, enable precision medicine, and improve patient access to clinical trials.

Back to Blog